XJPX6090
Market cap23mUSD
Jan 07, Last price
622.00JPY
1D
1.14%
1Q
3.32%
Jan 2017
-60.56%
IPO
-81.41%
Name
Human Metabolome Technologies Inc
Chart & Performance
P/E
15.10
P/S
2.73
EPS
41.18
Div Yield, %
1.60%
Shrs. gr., 5y
—
Rev. gr., 5y
6.32%
Revenues
1.35b
+3.57%
Net income
243m
-14.88%
CFO
237m
-16.90%
Dividend
Jun 27, 20250 JPY/sh
Profile
Human Metabolome Technologies, Inc., biotechnology company, develops metabolomics technologies and solutions for drug discovery, diagnosis, and food production in Japan. The company provides metabolome analysis services; and global profiling, targeted assays, flux analysis, and lipidomics services. It also develops biomarkers, such as Phosphorylethanolamine, a biomarker for major depressive disorder and measured in blood plasma. The company offers solutions for cancer metabolism, metabolic flux analysis, infectious diseases, basic science, preclinical and clinical, food and nutrition, and microbiome applications. It has a collaboration with the Institute for Advanced Biosciences and Keio University for the development of metabolome analysis technology. The company was incorporated in 2003 and is based in Tsuruoka, Japan.
Valuation
Title JPY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|
| 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | |
| Income | |||||
Revenues | 1,345,671 3.57% | 1,299,225 6.21% | 1,223,281 8.83% | ||
Cost of revenue | 1,116,829 | 1,078,473 | 1,027,276 | ||
Unusual Expense (Income) | |||||
NOPBT | 228,842 | 220,752 | 196,005 | ||
NOPBT Margin | 17.01% | 16.99% | 16.02% | ||
Operating Taxes | 18,654 | (48,756) | (5,874) | ||
Tax Rate | 8.15% | ||||
NOPAT | 210,188 | 269,508 | 201,879 | ||
Net income | 243,248 -14.88% | 285,758 6.71% | 267,785 360.00% | ||
Dividends | (58,696) | ||||
Dividend yield | 1.57% | ||||
Proceeds from repurchase of equity | (23) | ||||
BB yield | 0.00% | ||||
| Debt | |||||
Debt current | 214,959 | 213,361 | 209,864 | ||
Long-term debt | 37,647 | 39,681 | 56,526 | ||
Deferred revenue | (183) | (1,241) | |||
Other long-term liabilities | 12,737 | 12,563 | 12,541 | ||
Net debt | (1,542,900) | (1,410,747) | (1,245,354) | ||
| Cash flow | |||||
Cash from operating activities | 236,795 | 284,962 | 324,033 | ||
CAPEX | (34,099) | (116,855) | (146,114) | ||
Cash from investing activities | (32,441) | (116,755) | (152,314) | ||
Cash from financing activities | (73,153) | (13,754) | 80,491 | ||
FCF | 149,238 | 241,676 | 100,177 | ||
| Balance | |||||
Cash | 1,788,506 | 1,656,789 | 1,504,744 | ||
Long term investments | 7,000 | 7,000 | 7,000 | ||
Excess cash | 1,728,222 | 1,598,828 | 1,450,580 | ||
Stockholders' equity | 1,940,036 | 1,768,798 | 14,663 | ||
Invested Capital | 457,381 | 404,045 | 1,683,601 | ||
ROIC | 48.80% | 25.82% | 12.22% | ||
ROCE | 10.47% | 11.02% | 11.53% | ||
| EV | |||||
Common stock shares outstanding | 5,913 | 5,905 | 5,900 | ||
Price | 632.00 -15.62% | 749.00 2.60% | 730.00 -15.61% | ||
Market cap | 3,737,012 -15.51% | 4,422,787 2.69% | 4,307,137 -15.66% | ||
EV | 2,194,112 | 3,012,040 | 3,061,783 | ||
EBITDA | 315,157 | 301,138 | 260,901 | ||
EV/EBITDA | 6.96 | 10.00 | 11.74 | ||
Interest | 2,095 | 2,265 | 2,214 | ||
Interest/NOPBT | 0.92% | 1.03% | 1.13% | ||